Abstract
ABSTRACTObjective: To characterize metabolic control and verify whether it has any relation with socioeconomic, demographic, and body composition variables in children and adolescents with phenylketonuria (PKU) diagnosed in the neonatal period.Methods: This cohort study collected retrospective data of 53 phenylketonuric children and adolescents. Data on family income, housing, and mother’s age and schooling level were collected, and anthropometric measures of body composition and distribution were taken. All dosages of phenylalanine (Phe) from the last five years (2015-2019) were evaluated and classified regarding their adequacy (cutoffs: 0-12 years: 2-6 mg/dL; 12-19 years: 2-10 mg/dL). Adequate metabolic control was considered if ≥7%) of the dosages were within desired ranges.Results: The mean (±standard deviation) age in the last year was 10.1±4.6 years. Most of them were under 12 years old (33/53; 62.3%) and had the classic form of the disease (39/53; 73.6%). Better metabolic control was observed among adolescents (68.4 versus 51.4%; p=0.019). Overweight was found in 9/53 (17%) and higher serum Phe levels (p<0.001) were found in this group of patients. Metabolic control with 70% or more Phe level adequacy decreased along with the arm muscle area (AMA) (ptendency=0.042), being 70.0% among those with low reserve (low AMA), and 18.5% among those with excessive reserve (high AMA).Conclusions: Adequate metabolic control was observed in most patients. The findings suggest that, in this sample, the levels of phenylalanine may be related to changes in body composition.
Highlights
IntroductionPhenylketonuria (PKU) is a metabolic disease resulting from the accumulation of blood phenylalanine (Phe), which crosses the blood-brain barrier, implying neurotoxicity, and is characterized by intellectual disability (ID) when not diagnosed and treated early.[1] Treatment consists of a restricted diet of Phe for life, being effective to avoid neurocognitive sequelae, especially when started in the first days of life.[2]
The findings suggest that, in this sample, the levels of phenylalanine may be related to changes in body composition
Phenylketonuria (PKU) is a metabolic disease resulting from the accumulation of blood phenylalanine (Phe), which crosses the blood-brain barrier, implying neurotoxicity, and is characterized by intellectual disability (ID) when not diagnosed and treated early.[1]
Summary
Phenylketonuria (PKU) is a metabolic disease resulting from the accumulation of blood phenylalanine (Phe), which crosses the blood-brain barrier, implying neurotoxicity, and is characterized by intellectual disability (ID) when not diagnosed and treated early.[1] Treatment consists of a restricted diet of Phe for life, being effective to avoid neurocognitive sequelae, especially when started in the first days of life.[2]. In addition to neurocognitive damage, phenylketonuric patients without metabolic control are at increased risk of being overweight,[5,6] and girls are more likely to it.[7] A previous study conducted at eight European centers suggested early monitoring and intervention to prevent and control overweight.[8]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
